Annex Advisory Services LLC Raises Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Annex Advisory Services LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,572 shares of the medical research company’s stock after acquiring an additional 515 shares during the quarter. Annex Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $5,302,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in TMO. Montis Financial LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $371,000. HCR Wealth Advisors boosted its position in Thermo Fisher Scientific by 9.5% during the third quarter. HCR Wealth Advisors now owns 7,445 shares of the medical research company’s stock valued at $4,606,000 after purchasing an additional 647 shares in the last quarter. Ritholtz Wealth Management raised its holdings in Thermo Fisher Scientific by 7.7% in the third quarter. Ritholtz Wealth Management now owns 4,772 shares of the medical research company’s stock worth $2,952,000 after purchasing an additional 341 shares in the last quarter. Covea Finance boosted its holdings in shares of Thermo Fisher Scientific by 17.4% in the 3rd quarter. Covea Finance now owns 104,611 shares of the medical research company’s stock valued at $64,709,000 after buying an additional 15,500 shares in the last quarter. Finally, Guinness Atkinson Asset Management Inc grew its position in shares of Thermo Fisher Scientific by 17.1% in the 3rd quarter. Guinness Atkinson Asset Management Inc now owns 11,258 shares of the medical research company’s stock worth $6,964,000 after buying an additional 1,646 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.5 %

NYSE TMO opened at $596.92 on Friday. The business has a fifty day moving average price of $607.73 and a 200 day moving average price of $583.44. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The company has a market cap of $228.02 billion, a P/E ratio of 37.03, a P/E/G ratio of 3.80 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.15 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. TD Cowen boosted their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and set a $767.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 20th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Stifel Nicolaus raised their target price on Thermo Fisher Scientific from $615.00 to $680.00 and gave the stock a “buy” rating in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $653.72.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.